Optimized production and fluorescent labelling of SARS-CoV-2 Virus-Like-Particles to study virus assembly and entry.
D. Muriaux, M. Gourdelier, J. M. Swain, C. Arone, A. Mouttou, D. Bracquemond, P. Merida, S. Saffarian, S. Lyonnais, C. Favard
Abstract
SARS-CoV-2 is an RNA enveloped virus responsible for the COVID-19 pandemia that conducted in 6 million deaths worldwide so far. SARS-CoV-2 particles are mainly composed of the 4 main structural proteins M, N, E and S to form 100nm diameter viral particles. Based on productive assays, we propose an optimal transfected plasmid ratio mimicking the virus RNA ratio allowing SARS-CoV-2 Virus-Like Particle (VLPs) formation composed of the viral structural proteins M, N, E and S. Furthermore, monochrome, dual-color fluorescent or photoconvertible VLPs were produced. Thanks to live fluorescence and super-resolution microscopy, we quantified VLPs size and concentration. It shows a diameter of 110 and 140 nm respectively for MNE-VLPs and MNES-VLPs with a minimum concentration of 10e12 VLP/ml. SARS-CoV-2 VLPs could tolerate the integration of fluorescent N and M tagged proteins without impairing particle assembly. In this condition, we were able to establish incorporation of the mature Spike in fluorescent VLPs. The Spike functionality was then shown by monitoring fluorescent MNES-VLPs docking and endocytosis in human pulmonary cells expressing the receptor hACE2. This work provides new insights on the use of non-fluorescent and fluorescent VLPs to study and visualize the SARS-CoV-2 viral life cycle in a safe environment (BSL-2 instead of BSL-3). Moreover, optimized SARS-CoV-2 VLP production can be further adapted to vaccine design strategies.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Minimal system for assembly of SARS-CoV-2 virus like particles
H. Swann, A. Sharma, … S. Saffarian·Scientific ReportsPeer-reviewed·Dec 14, 2020
- SARS-CoV2 associated secretion of nanoLuciferase reports on virus and Virus-Like Particle production
Rebekah C. Gullberg, Judith Frydman·bioRxiv·Oct 11, 2022
- Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles
G. Elfayres, R. R. Paswan, … L. Berthoux·bioRxiv·Jul 24, 2023
- SARS-CoV-2 viral budding and entry can be modeled using virus-like particles
C. B. Plescia, E. A. David, … R. V. Stahelin·bioRxiv·Sep 30, 2020
- Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate
K. Arora, R. Rastogi, … P. K. Kundu·bioRxiv·May 18, 2020
- Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
M. Caruso, S. Roy, … P. O. de Campos-Lima·bioRxiv·Sep 16, 2020